Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

NDAQ:VRTX) Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xeris Pharmaceuticals (XERS – Research Report), Quanterix ...

Before you risk a nickel on this volatile biotech stock, you should know that sales of Casgevy haven't gotten off the ground yet. The company's collaboration partner, Vertex Pharmaceuticals(NASDAQ: ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Find investment ideas for your portfolio with the latest stock picks from Barron’s below. These picks are the product of the Barron’s newsroom and are our best ideas based on original ...

The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. We recently compiled a list of the 10 Best Penny Stocks to Buy for 2025. In this ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...